As of December, 2012, these drugs have generally failed in trials, either causing a marked increase in deaths (Torcetrapib), or having no meaningful clinical improvement despite HDL increases (Dalcetrapib).
•
Dalcetrapib, development halted in May 2012 when Phase III trials failed to show clinically meaningful efficacy.
inhibitor | Acetylcholinesterase inhibitor | Selective serotonin reuptake inhibitor | Enzyme inhibitor | enzyme inhibitor | Metalloprotease inhibitor | Matrix metalloproteinase inhibitor | Inhibitor | Farnesyltransferase inhibitor | COX-2 inhibitor | ALK inhibitor | ACE inhibitor |